Methylprednisolone aceponate
Star1
This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.
Explore a selection of our essential drug information below, or:
Identification
- Summary
Methylprednisolone aceponate is a corticosteroid indicated in the treatment of corticosteroid-responsive dermatoses.
- Generic Name
- Methylprednisolone aceponate
- DrugBank Accession Number
- DB14643
- Background
Not Available
- Type
- Small Molecule
- Groups
- Approved, Vet approved
- Structure
- Weight
- Average: 472.578
Monoisotopic: 472.246103499 - Chemical Formula
- C27H36O7
- Synonyms
- Aceponato de metilprednisolona
- Methylprednisolone aceponate
- Methylprednisoloni aceponas
- External IDs
- BRN 5663614
- SH-440
- ZK91588
Pharmacology
- Indication
Not Available
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Associated Conditions
Indication Type Indication Combined Product Details Approval Level Age Group Patient Characteristics Dose Form Symptomatic treatment of Allergic contact eczema •••••••••••• ••••• Symptomatic treatment of Atopic dermatitis (ad) •••••••••••• •••••• ••••••••• •••••••• Symptomatic treatment of Dermatitis, eczematous •••••••••••• •••••• ••••••••• •••••••• Treatment of Dermatitis, eczematous •••••••••••• Symptomatic treatment of Eczema, contact •••••••••••• •••••• ••••••••• •••••••• - Contraindications & Blackbox Warnings
- Prevent Adverse Drug Events TodayTap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events with our Clinical API
- Pharmacodynamics
Not Available
- Mechanism of action
- Not Available
- Absorption
Not Available
- Volume of distribution
Not Available
- Protein binding
Not Available
- Metabolism
- Not Available
- Route of elimination
Not Available
- Half-life
Not Available
- Clearance
Not Available
- Adverse Effects
- Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!Improve decision support & research outcomes with our structured adverse effects data.
- Toxicity
Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Drug Interaction Integrate drug-drug
interactions in your softwareAcarbose The risk or severity of hyperglycemia can be increased when Methylprednisolone aceponate is combined with Acarbose. Aceclofenac The risk or severity of gastrointestinal irritation can be increased when Methylprednisolone aceponate is combined with Aceclofenac. Acemetacin The risk or severity of gastrointestinal irritation can be increased when Methylprednisolone aceponate is combined with Acemetacin. Acenocoumarol Methylprednisolone aceponate may increase the anticoagulant activities of Acenocoumarol. Acetohexamide The risk or severity of hyperglycemia can be increased when Methylprednisolone aceponate is combined with Acetohexamide. - Food Interactions
- Not Available
Products
- Drug product information from 10+ global regionsOur datasets provide approved product information including:dosage, form, labeller, route of administration, and marketing period.Access drug product information from over 10 global regions.
- International/Other Brands
- Advantan
Categories
- ATC Codes
- D07AC14 — Methylprednisolone aceponate
- Drug Categories
- Chemical TaxonomyProvided by Classyfire
- Description
- This compound belongs to the class of organic compounds known as gluco/mineralocorticoids, progestogins and derivatives. These are steroids with a structure based on a hydroxylated prostane moiety.
- Kingdom
- Organic compounds
- Super Class
- Lipids and lipid-like molecules
- Class
- Steroids and steroid derivatives
- Sub Class
- Pregnane steroids
- Direct Parent
- Gluco/mineralocorticoids, progestogins and derivatives
- Alternative Parents
- Steroid esters / 20-oxosteroids / 3-oxo delta-1,4-steroids / 11-beta-hydroxysteroids / Delta-1,4-steroids / Alpha-acyloxy ketones / Dicarboxylic acids and derivatives / Secondary alcohols / Cyclic ketones / Cyclic alcohols and derivatives show 3 more
- Substituents
- 11-beta-hydroxysteroid / 11-hydroxysteroid / 20-oxosteroid / 3-oxo-delta-1,4-steroid / 3-oxosteroid / Alcohol / Aliphatic homopolycyclic compound / Alpha-acyloxy ketone / Carbonyl group / Carboxylic acid derivative show 15 more
- Molecular Framework
- Aliphatic homopolycyclic compounds
- External Descriptors
- Not Available
- Affected organisms
- Not Available
Chemical Identifiers
- UNII
- ET54W9J4U2
- CAS number
- 86401-95-8
- InChI Key
- DALKLAYLIPSCQL-YPYQNWSCSA-N
- InChI
- InChI=1S/C27H36O7/c1-6-23(32)34-27(22(31)14-33-16(3)28)10-8-19-18-11-15(2)20-12-17(29)7-9-25(20,4)24(18)21(30)13-26(19,27)5/h7,9,12,15,18-19,21,24,30H,6,8,10-11,13-14H2,1-5H3/t15-,18-,19-,21-,24+,25-,26-,27-/m0/s1
- IUPAC Name
- (1R,3aS,3bS,5S,9aR,9bS,10S,11aS)-1-[2-(acetyloxy)acetyl]-10-hydroxy-5,9a,11a-trimethyl-7-oxo-1H,2H,3H,3aH,3bH,4H,5H,7H,9aH,9bH,10H,11H,11aH-cyclopenta[a]phenanthren-1-yl propanoate
- SMILES
- [H][C@@]12CC[C@](OC(=O)CC)(C(=O)COC(C)=O)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])C[C@H](C)C2=CC(=O)C=C[C@]12C
References
- General References
- AIFA Package Leaflet: ADVANTAN (Methylprednisolone aceponate) for cutaneous use [Link]
- External Links
- ChemSpider
- 56717
- ChEBI
- 135762
- ChEMBL
- CHEMBL1697782
- ZINC
- ZINC000004213828
- Wikipedia
- Methylprednisolone_aceponate
Clinical Trials
- Clinical Trials
Clinical Trial & Rare Diseases Add-on Data Package
Explore 4,000+ rare diseases, orphan drugs & condition pairs, clinical trial why stopped data, & more. Preview package Phase Status Purpose Conditions Count Start Date Why Stopped 100+ additional columns Unlock 175K+ rows when you subscribe.View sample dataNot Available Completed Treatment Psoriasis Vulgaris (Plaque Psoriasis) 1 somestatus stop reason just information to hide 4 Completed Prevention Atopic Dermatitis 1 somestatus stop reason just information to hide 4 Completed Treatment Atopic Dermatitis 1 somestatus stop reason just information to hide 1 Completed Basic Science Normal Physiology 1 somestatus stop reason just information to hide 1 Completed Supportive Care Eczema; Contact, Allergic 1 somestatus stop reason just information to hide
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
Form Route Strength Cream Cutaneous 1 mg/g Cream Cutaneous 1.000 mg Solution Topical 1 mg/ml Emulsion Topical 0.1 g Ointment Topical Cream Topical 0.1 % Ointment Topical 0.1 percent Ointment Topical 0.1 % Solution Oral 0.1 % Emulsion Topical 0.1 % Solution Topical 0.1 % Lotion Topical 0.1 % Lotion Topical 100 gr Lotion Topical 50 gr Lotion Topical 100 mg Lotion Topical 10000000 mg Emulsion Topical Solution Oral 1 MG/ML Emulsion Topical 1 MG/G - Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Not Available
- Experimental Properties
- Not Available
- Predicted Properties
Property Value Source Water Solubility 0.00637 mg/mL ALOGPS logP 2.92 ALOGPS logP 3.14 Chemaxon logS -4.9 ALOGPS pKa (Strongest Acidic) 14.8 Chemaxon pKa (Strongest Basic) -2.9 Chemaxon Physiological Charge 0 Chemaxon Hydrogen Acceptor Count 5 Chemaxon Hydrogen Donor Count 1 Chemaxon Polar Surface Area 106.97 Å2 Chemaxon Rotatable Bond Count 7 Chemaxon Refractivity 125.97 m3·mol-1 Chemaxon Polarizability 50.86 Å3 Chemaxon Number of Rings 4 Chemaxon Bioavailability 1 Chemaxon Rule of Five Yes Chemaxon Ghose Filter Yes Chemaxon Veber's Rule No Chemaxon MDDR-like Rule Yes Chemaxon - Predicted ADMET Features
- Not Available
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
Spectrum Spectrum Type Splash Key Predicted MS/MS Spectrum - 10V, Positive (Annotated) Predicted LC-MS/MS splash10-0abj-0005900000-6949032568b643e59f69 Predicted MS/MS Spectrum - 10V, Negative (Annotated) Predicted LC-MS/MS splash10-0abi-9006500000-bf9b149ea1f1cc07e254 Predicted MS/MS Spectrum - 20V, Negative (Annotated) Predicted LC-MS/MS splash10-0adi-9006000000-5771696f58ddd9e5c60c Predicted MS/MS Spectrum - 20V, Positive (Annotated) Predicted LC-MS/MS splash10-0a4i-0214900000-f80e0b0f5c2ffbeaff9a Predicted MS/MS Spectrum - 40V, Negative (Annotated) Predicted LC-MS/MS splash10-00dl-9004000000-2e1c43fdf0a2e99b8176 Predicted MS/MS Spectrum - 40V, Positive (Annotated) Predicted LC-MS/MS splash10-0002-0941200000-7b73c66cbf5faa66a407 Predicted 1H NMR Spectrum 1D NMR Not Applicable Predicted 13C NMR Spectrum 1D NMR Not Applicable - Chromatographic Properties
Collision Cross Sections (CCS)
Adduct CCS Value (Å2) Source type Source [M-H]- 226.5826853 predictedDarkChem Lite v0.1.0 [M-H]- 205.19638 predictedDeepCCS 1.0 (2019) [M+H]+ 226.9043853 predictedDarkChem Lite v0.1.0 [M+H]+ 207.02129 predictedDeepCCS 1.0 (2019) [M+Na]+ 227.1197853 predictedDarkChem Lite v0.1.0 [M+Na]+ 213.26285 predictedDeepCCS 1.0 (2019)
Drug created at September 01, 2018 21:20 / Updated at May 14, 2021 01:07